Banque Pictet & Cie Sa Argenx Se Transaction History

Banque Pictet & Cie Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$334.23 - $403.65 $396,731 - $479,132	-1,187 Reduced 23.71%	3,820 $1.42 Million
Q4 2022 Feb 06, 2023	SELL	$342.17 - $402.31 $995,372 - $1.17 Million	-2,909 Reduced 36.75%	5,007 $0
Q3 2022 Nov 10, 2022	SELL	$343.2 - $395.75 $10,296 - $11,872	-30 Reduced 0.38%	7,916 $2.79 Billion
Q2 2022 Aug 08, 2022	SELL	$269.58 - $378.88 $205,959 - $289,464	-764 Reduced 8.77%	7,946 $3.01 Million
Q1 2022 May 04, 2022	SELL	$254.45 - $351.06 $3.73 Million - $5.15 Million	-14,662 Reduced 62.73%	8,710 $2.75 Million
Q4 2021 Feb 02, 2022	BUY	$272.01 - $353.03 $6.36 Million - $8.25 Million	23,372 New	23,372 $8.19 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.